Context

Over the last 20 years, little has changed in terms of HIV treatment paradigm, being a three-drug regimen the standard of care for initial therapy. However, for reasons of virological plausibility, toxicity and costs, clinical researchers have explored the alternatives of switching virologically controlled patients to less-drug regimens (ie, dual or monotherapy). Several randomised trials1 investigated the ritonavir-boosted protease inhibitor monotherapy (PI-mono), on the grounds of absence of resistance mutations …